Figure 1 | Scientific Reports

Figure 1

From: JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide

Figure 1

JAM-A overexpression was related to extranodal involvement and poor disease outcome in DLBCL. (A,B) JAM-A gene (A) and JAM-A protein (B) were overexpressed in DLBCL. (C) JAM-A gene expression correlated well with JAM-A protein expression. (D) DLBCL patients with extranodal involvement had higher JAM-A gene and JAM-A protein expression than those only with nodal lesions. (E) Patients in high JAM-A expression group had poor progression-free survival (PFS).

Back to article page